Anti-KIR4.1 Antibodies in Chinese Patients with Central Nervous System Inflammatory Demyelinating Disorders

Area of Science:

• Neuroimmunology
• Autoimmunity
• Biomarker Discovery

Background:

• Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
• Identifying specific biomarkers for MS is crucial for diagnosis and treatment.
• KIR4.1 antibodies have been investigated as potential biomarkers in neurological disorders.

Purpose of the Study:

• To determine the frequency of KIR4.1 antibodies in patients with multiple sclerosis (MS).
• To compare KIR4.1 antibody levels in MS patients against various control groups.
• To evaluate the specificity of KIR4.1 antibodies as a biomarker for MS using a cell-based assay.

Main Methods:

• Established a transfected HEK-293A cell line expressing KIR4.1.
• Tested blood serum from 904 subjects for the presence of KIR4.1 antibodies.
• Included patients with MS, neuromyelitis optica spectrum disorders (NMOSD), other inflammatory neurologic disease (OIND), other noninflammatory neurological disease (OND), and healthy controls.

Main Results:

• KIR4.1 antibodies were detected in 12.2% of MS patients.
• Antibody frequencies in MS patients were comparable to those in NMOSD (15.9%), OIND (15.3%), OND (11.8%), and healthy controls (5%).
• No statistically significant differences in KIR4.1 antibody prevalence were observed between the MS group and control groups (p = 0.279).

Conclusions:

• Anti-KIR4.1 antibody detection via cell-based assay is not a specific biomarker for multiple sclerosis.
• The findings suggest that KIR4.1 antibodies may not be a reliable diagnostic marker for MS.
• Further research is needed to understand the role of KIR4.1 antibodies in MS pathogenesis.